vTv Therapeutics to Participate in September Investor Conferences
Management at vTv Therapeutics is set for a fireside chat and one-on-ones at H.C. Wainwright Sept. 16 and ROTH Healthcare Sept. 29.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
vTv Therapeutics (VTVT) will participate in two investor conferences in September 2026 to discuss its late-stage work on cadisegliatin, an oral investigational therapy for type 1 diabetes. Management will join a fireside chat and one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 16 in New York and hold one-on-one investor meetings at the 5th Annual ROTH Healthcare Opportunities Conference on September 29.
Details
News Market Reaction – VTVT
On Sep 2, the day this news came out, VTVT closed 4.54% above the previous close. Argus tracked a peak move of +2.1% during that session. Our momentum scanner recorded 5 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Publication Date
- September 2, 2026
- Article dateline
- Conference Edition
- 28th annual
- H.C. Wainwright Global Investment Conference
- Conference Date
- September 16, 2026
- H.C. Wainwright conference
- Fireside Chat Time
- 10:00-10:30 AM ET
- H.C. Wainwright conference
- Conference Edition
- 5th annual
- ROTH Healthcare Opportunities Conference
- Conference Date
- September 29, 2026
- ROTH Healthcare Opportunities Conference
Historical Context
-
Granted 2,500 employee stock options under Nasdaq inducement rules.
-
Reported second-quarter results and provided updates on CATT1 enrollment.
-
Granted 23,500 employee stock options under the 2026 Inducement Plan.
-
Granted 12,500 employee stock options at a weighted average exercise price.
-
Granted 2,500 options to a new non-executive employee.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
t1d medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September:
H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat and one-on-one investor meetings
Date: Wednesday, September 16, 2026
Time: 10:00-10:30 AM ET
Location: New York, NY
Webcast Link
5th Annual ROTH Healthcare Opportunities Conference
Format: One-on-one investor meetings
Date: Tuesday, September 29, 2026
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for T1D. In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What investor conferences will vTv Therapeutics (VTVT) attend in September 2026?
vTv Therapeutics will attend the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, in New York, and the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026. Management plans fireside and one-on-one investor meetings.
When is vTv Therapeutics (VTVT) presenting at the H.C. Wainwright 28th Annual Global Investment Conference?
The company’s fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference is scheduled for Wednesday, September 16, 2026, from 10:00 to 10:30 AM ET in New York, NY, with additional one-on-one investor meetings.
What is the format of vTv Therapeutics (VTVT) participation at the H.C. Wainwright conference?
At the H.C. Wainwright 28th Annual Global Investment Conference, vTv Therapeutics management will take part in a fireside chat and hold one-on-one investor meetings. A webcast link is indicated for the session for remote access.
How is vTv Therapeutics (VTVT) participating in the 5th Annual ROTH Healthcare Opportunities Conference?
At the 5th Annual ROTH Healthcare Opportunities Conference on Tuesday, September 29, 2026, vTv Therapeutics management will conduct one-on-one investor meetings. No separate fireside chat or presentation time is specified in the announcement.
What drug program will vTv Therapeutics (VTVT) highlight at these September 2026 conferences?
vTv Therapeutics describes itself as a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D). This late-stage program is the core focus likely to be discussed with investors.